Blog - Page 7 of 12 - COPE

COPE supported centers are pleased to provide a blog for patients and family members of patients that provides more information on ketamine treatments and mental illness.


Relative Efficacy Ketamine : Does the Formulation and Delivery Matter with Respect to Efficacy, Tolerability and Safety?

In March of 2019, the US FDA approved intranasal esketamine for treatment-resistant depression (TRD). Conceptually, this is an extraordinary event from the point of view of drug development in psychiatry insofar as this is the first time the FDA has approved an antidepressant medicine that was developed on the basis of an a priori diseases model (i.e. glutamatergic dysregulation relevant to the pathogenesis of mood disorders).

Can We Predict Who will Respond to Ketamine/Esketamine in TRD?

Treatment resistant depression
The heterogeneity of treatment response in MDD has provided a compelling rationale for identifying predictors of response/tolerability (and non-response/intolerability) amongst individuals assigned to a given treatment. The need to identify predictors of response is even greater when the treatment options being considered are more costly, require more resources for administration (e.g. specialized clinics), and/or may be associated with greater safety/tolerability concerns.

Esketamine (Spravato): What You Need To Know About Breakthrough The Nasal Spray

There’s tons of excitement in psychiatry after the US Food and Drug Administration advisory committee recently backed esketamine (Spravato), an intranasal form of ketamine for treatment-resistant depression. This is an exciting and hopeful advancement because there hasn’t been a different pharmacologic depression treatment target approved by the agency in decades (Think: Prozac’s arrival in 1986). Like any new drug, the excitement and hope surrounding esketamine (Spravato) needs to be weighed by risks and benefits. Here are a few things you need to know about esketamine (Spravato).